Authors

Further Integrating Biosimilars into Oncology: The Role of WYOST (denosumab-bbdz) in Preventing Cancer-Related Skeletal Events with Bone Metastases from Solid Tumors

Cancer patients facing skeletal-related events may benefit from WYOST®, the first FDA-approved biosimilar for this condition, offering safe, effective, and more affordable treatment for bone complications.

US Biosimilar Portfolio Hits 10-Year Mark in Growth Mode

Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.

Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic Cancer

Although a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.

Rethinking Lung Cancer Screening Paradigms

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.

Struggling With COVID-19 on the Cancer Floor

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Career Options for Graduating Oncology Fellows at the NIH and FDA

Peter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.

Biology, Compassion, and Patience Motivate Stock as a Pioneer in Leukemia

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

Dr Mar on Challenges With ARPI Rechallenge in Prostate Cancer

Nataliya Mar, MD, discusses attempts to develop mechanisms for resensitizing prostate tumors to ARPI rechallenge.

Kay Macleod Named Associate Director for Basic Sciences for the Cancer Center

Kay Macleod, PhD, has been appointed as the associate director for Basic Sciences for the University of Chicago Medicine Comprehensive Cancer Center.

Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities

Henry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Gymnastics Makes Me a Better Oncologist

Valentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.

ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy

The Association of Community Cancer Centers announced that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.

Smoking Cessation Support Plays a Vital Role in Improving Lung Cancer Screening

Results of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Nogapendekin Alfa Inbakicept Plus BCG Favored Over Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma

Doris Hansen, MD, discusses the potential role of GPRC5D-directed CAR T-cell therapy with arlo-cel in patients with multiple myeloma.

ChatGPT, M.D.? Evaluating Chatbot Accuracy in the Fast-Changing Blood Cancer Field

Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Integrating New Standards for Metastatic HER2+ Breast Cancer

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Our Path Forward in Leading a Revolution in Cancer Care

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Hackensack Meridian Health Partners with DELFI Diagnostics, Supported by a Grant from Lilly to Improve Lung Cancer Screening Adherence With Innovative Blood Test

The initiative aims to increase uptake of life-saving LDCT scans for high-risk individuals in line with guidance via a minimally invasive blood test.

Extending Overall Survival in Patients with Advanced Urothelial Carcinoma

ADC Cast: ADC antigen targets: What are we aiming at?

This is a featured episode from an educational podcast series with expert discussions on antibody drug conjugates, intended for US healthcare professionals.